Monopar Therapeutics (MNPR) Times Interest Earned (2017 - 2026)

Monopar Therapeutics (MNPR) posted Times Interest Earned of -$36.94 for Q3 2025, down 41.73% sequentially from -$26.06 in Q2 2025.

Monopar Therapeutics (MNPR) Times Interest Earned (2017 - 2026) Analysis & Trends

Monopar Therapeutics has reported Times Interest Earned for 7 years, with the latest figure at -$36.94 in Q3 2025.

Quarterly Times Interest Earned changed N/A year-over-year to -$36.94 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$109.42 (changed N/A YoY) and the FY2025 annual result came in at $0.38, up 187.73% from the prior year.
Times Interest Earned eased to -$36.94 in Q3 2025 per MNPR's latest filing, from -$26.06 in the prior quarter.
Over five years, Times Interest Earned peaked at -$0.26 in Q4 2022 and troughed at -$805454.2 in Q1 2025.
A 3-year average of -$100847.0 and a median of -$34.77 in 2022 frame the typical range for Times Interest Earned.
The sharpest annual moves came in 2021 and 2022: Times Interest Earned gained 19.81% in 2021, then grew 24.82% in 2022.
Over 3 years, Times Interest Earned stood at -$0.35 in 2021, then climbed by 24.82% to -$0.26 in 2022, then plunged by 14048.61% to -$36.94 in 2025.
According to Business Quant data, Times Interest Earned over the past three periods registered -$36.94, -$26.06, and -$805454.2 for Q3 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.84
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	24.64
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-0.19
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	8.18
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.01
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.61
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.82
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.08
10	Monopar Therapeutics	965.64 Mn	912.88 Mn	-	-30.14

Download Data